Ergocalciferol
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ergocalciferol: From Vitamin D Deficiency to Familial Isolated Hypoparathyroidism
One-Sentence Summary
Ergocalciferol (Vitamin D2) is an established vitamin D compound used internationally for vitamin D deficiency and related bone disorders, though no South African regulatory indication text is available in this Evidence Pack. The TxGNN model predicts it may be effective for familial isolated hypoparathyroidism due to impaired PTH secretion, but this ranking currently has 0 clinical trials and 0 publications supporting it — the prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not established in the SA registry (Evidence Pack shows no SAHPRA licenses); internationally, ergocalciferol is used for vitamin D deficiency and nutritional rickets |
| Predicted New Indication | Familial isolated hypoparathyroidism due to impaired PTH secretion |
| TxGNN Prediction Score | 99.85% |
| Evidence Level | L5 (model prediction only, no clinical trials or literature) |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for ergocalciferol is not available in this Evidence Pack (flagged as a High-severity data gap). Based on general pharmacology, ergocalciferol (Vitamin D2) requires hepatic 25-hydroxylation and renal 1α-hydroxylation to reach its active form, which promotes intestinal calcium absorption.
For this specific candidate, the model’s own rationale is cautious: activated vitamin D could theoretically compensate for the hypocalcemia that results from impaired PTH secretion, but it has no direct mechanistic link to the disease’s root cause — a defect in PTH secretion itself. The relationship is described as only a downstream, supportive link to calcium homeostasis, not a targeted treatment of the underlying pathology. This is consistent with the complete absence of clinical trial or literature evidence for this specific rare disease.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
No SAHPRA registrations are recorded in the Evidence Pack for ergocalciferol — market status is Not marketed (0 licenses on file). No product name, dosage form, or approved indication text is currently available for South Africa.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate has no clinical trial or literature evidence at all, and the model’s own mechanistic rationale explicitly notes the link is indirect (supportive calcium correction) rather than disease-specific. This is a pure L5 model prediction and does not currently support further evaluation.
To proceed, the following is needed:
- Detailed mechanism of action (MOA) data for ergocalciferol (currently a data gap)
- SAHPRA-approved Professional Information — warnings, contraindications, and safety data (currently a Blocking data gap)
- Targeted literature and clinical trial search specific to familial isolated hypoparathyroidism
- Confirmation of South African market/registration status, since none is currently on file
Note: within this same Evidence Pack, two other candidates for ergocalciferol — hypophosphatemia (disease) and renal osteodystrophy — carry substantially stronger evidence (L2, “Proceed with Guardrails,” with completed/ongoing trials and multiple cohort studies) and may warrant separate evaluation if this drug is being considered for repurposing.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.